Skip to content
Screener

Bristol-Myers Squibb BMY Q2 2025 earnings

Reported July 31, 2025 · Before market open

Revenue$12.3BBeat by $824.8M
EPS$1.46Beat by $0.37
Revenue estimate$11.4B
EPS estimate$1.09

Next report

Oct 29, 2026 (In 3 weeks)
Revenue estimate$12.6B
EPS estimate$1.68

Financials

Q2 2025

Income statement

See full
Revenue$12.3B+0.6%
Gross profit$8.9B-0.4%
Net income$1.3B-22.0%
EPS (diluted)$0.64-22.9%

Balance sheet

See full
Cash & equivalents$12.6B+100%
Total debt$49.4B-6.1%
Total equity$17.4B+2.5%
Total assets$94.7B0.0%

Cash flow

See full
Operating cash flow$3.9B+68.4%
CapEx$361.0M+37.8%
Free cash flow$3.6B+72.3%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$95.71B+13.7%
Enterprise value$132.49B+1.6%
P/E19.2×—
P/S2×+0.2×

Profitability

See full
Gross margin70.3%-5.1pp
Net margin10.4%+6.6pp
FCF margin30.6%+2.7pp

Returns & leverage

See full
Return on equity28.9%+19.5pp
Debt / equity2.8×-0.3×
Current ratio1.2×+0.1×

Segments

By product

See full
Eliquis$3.7B+7.7%
Opdivo$2.6B+7.2%
Orencia$963.0M+1.6%
Revlimid$838.0M-38.1%
Yervoy$728.0M+15.6%

By geography

See full
International$3.5B—
Other$270.0M+53.4%

FAQ

When did Bristol-Myers Squibb report Q2 2025 earnings?
Bristol-Myers Squibb (BMY) reported Q2 2025 earnings on July 31, 2025 before market open.
What were Bristol-Myers Squibb's Q2 2025 revenue and EPS?
Bristol-Myers Squibb reported revenue of $12.3B and eps of $1.46 for Q2 2025.
Did Bristol-Myers Squibb beat estimates in Q2 2025?
Revenue beat the consensus estimate of $11.4B by $824.8M. EPS beat the consensus estimate of $1.09 by $0.37.
How did Bristol-Myers Squibb's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.6% from $12.2B a year earlier and eps declined 29.5% from $2.07.
Where can I find Bristol-Myers Squibb's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000014272-25-000129) and the 10-Q periodic report (0000014272-25-000131) directly on SEC EDGAR. The filing index links above go to sec.gov.